International Stem Cell Corporation (OTCBB:ISCO)
has received the second $1 million tranche of an anticipated private
equity financing of up to $5 million to be funded over the next several
months. The total amount of the financing is intended to allow the
Company to move forward with its therapeutic research, including its
pre-clinical trials. The money will also help retire its existing
secured debt and be allocated to marketing to increase revenues in the
Company's subsidiary, Lifeline Cell Technology, which makes and sells
specialty cells and growth media.
ISCO is the creator and developer of a new class of stem cells that
remove two of the greatest barriers to the therapeutic use of stem
cells: 1) immune rejection and 2) the ethical issues that surround the
use of embryonic stem cells. ISCO makes its cells available to qualified
researchers worldwide, and its technology, called "Parthenogenesis,"
results in the creation of cell lines that may allow cells from a single
donor to be immune-matched to hundreds of millions of people thus
reducing the dangers of immune rejection.
For more information, visit the ISCO website at: www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications please click on
the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):
International Stem Cell Corporation is a California biotechnology
company focused on developing therapeutic and research products. ISCO's
technology, Parthenogenesis, results in the creation of pluripotent
human stem cell lines from unfertilized human eggs. ISCO scientists have
created the first Parthenogenetic homozygous stem cell line
(phSC-Hhom-4) that can be a source of therapeutic cells that will
minimize immune rejection after transplantation into hundreds of
millions of individuals of differing sexes, ages and racial groups.
These advancements offer the potential to create the first true "Stem
Cell Bank" and address ethical issues by eliminating the need to use or
destroy fertilized embryos. ISCO also produces and markets specialized
cells and growth media worldwide for therapeutic research through its
subsidiary Lifeline Cell Technology. For more information, visit the
ISCO website at: www.internationalstemcell.com.
FORWARD-LOOKING STATEMENTS: Statements pertaining to anticipated future financial and/or
operating results, future growth in research, technology, clinical
development and potential joint venture and other opportunities for the
company and its subsidiary, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements that
are not historical fact (including, but not limited to statements that
contain words such as "will," "believes," "plans," "anticipates,"
"expects," "estimates,") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and uncertainties,
including, without limitation, risks inherent in the development and/or
commercialization of potential products, uncertainty in the results of
clinical trials or regulatory approvals, need and ability to obtain
future capital, application of capital resources among competing uses,
and maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many
uncertainties that affect the company's business, particularly those
mentioned in the cautionary statements found in the company's Securities
and Exchange Commission filings. The company disclaims any intent or
obligation to update these forward-looking statements.
International Stem Cell Corporation Kenneth C. Aldrich, Chairman,
CEO kaldrich@intlstemcell.com 760-940-6383 or William
Adams, Chief Financial Officer wadams@intlstemcell.com 760-940-6383 or The
Investor Relations Group 212-825-3210 Investor Relations: Adam
S. Holdsworth aholdsworth@investorrelationsgroup.com or Media
Relations: Laura Colontrelle lcolontrelle@investorrelationsgroup.com |